Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism

T1Covered by 1 source · first reported by Nature / Science / Nature Biotechnology at 14 Oct, 00:00 UTC

Nature, Published online: 14 October 2026; doi:10.1038/s41586-026-11176-1 A tetravalent nanobody-based myeloid-selective IL-10 receptor agonist recapitulates IL-10’s potent suppression of monocytes, macrophages and dendritic cells while avoiding stimulation of T cells.

Sources

• T1Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonismNature / Science / Nature Biotechnology14 Oct, 00:00